You are here
ABZYME THERAPEUTICS LLC
UEI: H2MLEFWV36N6
# of Employees: 8
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Novel immune-escape uricase for treatment of hyperuricemia
Amount: $299,999.00Abstract. High serum urate levels (hyperuricemia) and subsequent monosodium urate crystal deposition cause gout, the most common inflammatory arthritis in men and postmenopausal women. Gout affects an ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis
Amount: $399,107.00Abstract. Central Nervous System (CNS) physical injuries, including bacterial or viral infection, can induce chronic neuroinflammation that is believed to persist for the lifetime of an individual. Am ...
SBIRPhase I2021Department of Health and Human Services National Institutes of Health -
Antibody Fragments to Improve HIV gp120 Protein Production
Amount: $299,815.00Camelid single domain antibody fragmentsVHHpossess a number of distinctive features including a small sizean elevated stabilityand an ability to recognize epitopes non accessible for conventional anti ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Pemphigus-specific T cell engagers for pemphigus targeted immunotherapy
Amount: $280,352.00ABSTRACTPemphiguspemphigus vulgarisPVand pemphigus foliaceusPFis an acquired autoimmune disease in which IgG antibodies target the keratinocyte desmosomal cadherin proteins desmogleinand desmogleinres ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases
Amount: $299,989.00ABSTRACTRetinal neovascular diseases including neovascular age related macular degenerationdiabetic macular edema and retinal vein occlusion are the most vision threatening diseases among the working ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Topic 373: Monoclonal Antibodies to RNA-modifications
Amount: $299,999.00Post-transcriptional RNA modification is quite complex as there are more than sixty known RNA modifications that occur in thousands of RNAs in eukaryotic cells. A number of these RNA modifications hav ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Medical Countermeasure Development for Viral Induced Encephalitis Using Single DomainAntibodies
Amount: $499,999.06Alphaviruses, infection with which may cause encephalitis and death, are recognized as potential biological warfare agents. There are noapproved medical countermeasures against Alphaviruses. In Phase ...
SBIRPhase II2018Department of Defense Office for Chemical and Biological Defense -
Modular antibody engineering to overcome the blood brain barrier
Amount: $236,646.00Abstract Immunotherapy is one of the most promising approaches for treatment of various human diseases including cancers autoimmune and infectious diseases However systemic immunotherapies have be ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Development Of Arginine Linkage Specific Antibodies
Amount: $224,926.00ASBTRACT Arginylation mediated by arginyltransferase ATE is a posttranslational modification that plays a global role in mammals Arginylation is essential for mammalian embryogenesis and regulati ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Human monoclonal antibodies as countermeasures for T-2 mycotoxin
Amount: $149,964.61Mycotoxins are fungal toxins to which exposure frequently results in incapacitation or even in death. Natural outbreaks of mycotoxin poisoningare common worldwide. Due to its physical-chemical propert ...
SBIRPhase I2016Department of Defense Office for Chemical and Biological Defense
